Health Condition 1: C801- Malignant (primary) neoplasm, unspecified
Conditions
Interventions
Intervention1: Dexamethasone & NEPA (Netupitant Plus Palonosetron): Oral Dexamethasone plus 300 mg Netupitant plus Palonosetron 0.5 mg on day 1 of each cycle.
Control Intervention1: Not Applicable: no
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: Willing to give Informed Consent confirmed diagnosis of Cancer ECOG performance status 0 to 2 Acceptable Hepatic and Renal function Parenteral Chemotherapy based on NCCN 2023
Exclusion criteria
Exclusion criteria: pregnant and lactating women Myocardial Infarction within last 6 months Known hypersensitivity to 5HT3RA or NK1RA and excipients Uncontrolled Diabetes Mellitus Nausea and vomiting at baseline Active peptic ulcer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| no emetic episode & no use of rescue medicationTimepoint: from day 1 to day 5 after HEC administration for maximum of 4 cycles | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of emesis-free patientsTimepoint: acute delayed & all single days of all CT cycles upto 4 cycles;Acute delayed & overall nauseaTimepoint: Acute delayed overall & all single days of CT cycles up to 4 cycles;Rescue medicationTimepoint: total duration of study;acute & delayed phase complete response of emesisTimepoint: acute phase 0 to 24 hours delayed phase 24 to 120 hours;complete control of nauseaTimepoint: acute phase 0 to 24 hours delayed phase 24 to 120 hours | — |
Countries
India
Contacts
Public ContactDr Sandeep Batra
Max Super Speciality Hospital Saket (A unit of Devki Devi Foundation)
Outcome results
None listed